Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 11;13:841126. doi: 10.3389/fimmu.2022.841126

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Burbelo, Castagnoli, Shimizu, Delmonte, Dobbs, Discepolo, Lo Vecchio, Guarino, Licciardi, Ramenghi, Rey-Jurado, Vial, Marseglia, Licari, Montagna, Rossi, Montealegre Sanchez, Barron, Warner, Chiorini, Espinosa, Noguera, Dropulic, Truong, Gerstbacher, Mató, Kanegaye, Tremoulet, Pediatric Emergency Medicine Kawasaki Group, Eisenstein, Su, Imberti, Poli, Burns, Notarangelo and Cohen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Longitudinal autoantibody profiles before and after administration of IVIG in MIS-C and KD patients. Antibody levels were determined in serial samples from representative MIS-C (MIS-C, Pt1-3) and KD patients (KD, Pt1-3), in which time zero represents the day of hospital admission. The autoantibody profiles for Ro52 (blue), Ro60 (red), La (green), and gastric ATPase (purple) are shown by the colored lines, in which the cut-off value for determining positivity is shown by the dotted lines. The arrow shows the day when IVIG was administered.